According to Steel et al. (n.d.), community-acquired pneumonia (CAP) is described as an acute infection of the lung parenchyma acquired in the community. It is most commonly bacterial in nature and is associated with clinical and/or radiological evidence of consolidation of part or parts of one or both lungs. The most commonly identified pathogens are Streptococcus pneumoniae, Haemophilus influenzae, a typical bacteria (i.e., Chlamydia pneumoniae, Mycoplasma pneumoniae, Legionella sp).
The diagnosis of CAP is based on the presence of clinical features and is supported by imaging of the lungs, usually by chest radiography. Various sign and symptoms include fever, cough, sputum production, pleuritic chest pain, dyspnea, tachypnea, and tachycardia. Older patients and those who are immune-compromised may not exhibit typical symptoms, such as fever. However, most patients present with at least one respiratory symptom, such as acute functional or cognitive decline. Many studies have suggested that the incidence of CAP is slightly higher in males as compared to females.
Get FREE sample copy at:
https://www.delveinsight.com/sample-request/community-acquired-bacterial-pneumonia-cabp-epidemiology-forecast
DelveInsight’s ‘Community-Acquired Bacterial Pneumonia (CABP) Epidemiology Forecast to 2030‘ report delivers an in-depth understanding of the disease, historical and forecasted Community-Acquired Bacterial Pneumonia (CABP) epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
The DelveInsight Community-Acquired Bacterial Pneumonia (CABP) epidemiology report gives a thorough understanding of the Community-Acquired Bacterial Pneumonia (CABP) disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides treatment algorithms and treatment guidelines for Community-Acquired Bacterial Pneumonia (CABP) in the US, Europe, and Japan. The report covers the detailed information of the Community-Acquired Bacterial Pneumonia (CABP) epidemiology scenario in seven major countries (US, EU5, and Japan).
Key Highlights Of The Report
According to the European Lung White Book, approximately 3,370,000 cases of CAP are reported annually in the European Union with 1 million hospitalizations. Furthermore, the adult incidence of CAP in Europe ranges from 1.7–11.6 cases/1,000 people/year.
The Center for Disease Control and Prevention (CDC) estimates that drug-resistant bacteria causes 2 million illnesses and approximately 23,000 deaths each year in the United States. The main bacteria causing CABP (Streptococcus pneumonia), is responsible for 1.2 million infections and 7,000 deaths annually.
Community-Acquired Bacterial Pneumonia (CABP) Epidemiology
- Delveinsight’s Community-Acquired Bacterial Pneumonia (CABP) epidemiology division provides insights about historical and current patient pool and forecasted trends for every seven major countries.
- The Community-Acquired Bacterial Pneumonia (CABP) epidemiology data are studied through all possible divisions to give a better understanding of the Disease scenario in 7MM.
- The Community-Acquired Bacterial Pneumonia (CABP) epidemiology segment covers the epidemiology data in the US, EU5 countries (Germany, Spain, Italy, France, and the UK), and Japan from 2017 to 2030.
- It also helps to recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.
- The report provides insight into the historical and forecasted patient pool of Community-Acquired Bacterial Pneumonia (CABP) in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan.
- The report assesses the disease risk and burden and highlights the unmet needs of Community-Acquired Bacterial Pneumonia (CABP).
- The report helps to recognize the growth opportunities in the 7MM with respect to the patient population.
- The Community-Acquired Bacterial Pneumonia (CABP) report provides a detailed overview explaining Community-Acquired Bacterial Pneumonia (CABP) causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns.
- The Community-Acquired Bacterial Pneumonia (CABP) Epidemiology Report and Model provide an overview of the risk factors and global trends of Community-Acquired Bacterial Pneumonia (CABP) in the seven major markets (7MM:US, France, Germany, Italy, Spain, UK, and Japan).
- The report provides the segmentation of the Community-Acquired Bacterial Pneumonia (CABP) epidemiology.
Key Benefit of Community-Acquired Bacterial Pneumonia (CABP) Epidemiology Report
The Community-Acquired Bacterial Pneumonia (CABP) Epidemiology report will allow the user to -
- Develop business strategies by understanding the trends shaping and driving the global Community-Acquired Bacterial Pneumonia (CABP) market
- Quantify patient populations in the global Community-Acquired Bacterial Pneumonia (CABP) market to improve product design, pricing, and launch plans
- Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Community-Acquired Bacterial Pneumonia (CABP) therapeutics in each of the markets covered
- Understand the magnitude of Community-Acquired Bacterial Pneumonia (CABP) population by its epidemiology
- The Community-Acquired Bacterial Pneumonia (CABP) Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources
Get FREE sample copy at:
https://www.delveinsight.com/sample-request/community-acquired-bacterial-pneumonia-cabp-epidemiology-forecast
- Key Insights
- Executive Summary of Community-Acquired Bacterial Pneumonia (CABP)
- Community-Acquired Bacterial Pneumonia (CABP) Disease Background and Overview
- Community-Acquired Bacterial Pneumonia (CABP) Patient Journey
- Community-Acquired Bacterial Pneumonia (CABP) Epidemiology and Patient Population
- Community-Acquired Bacterial Pneumonia (CABP) Treatment Algorithm, Current Treatment, and Medical Practices
- KOL Views on Community-Acquired Bacterial Pneumonia (CABP)
- Community-Acquired Bacterial Pneumonia (CABP) Unmet Needs
- Appendix
- DelveInsight Capabilities
- Disclaimer
*The table of contents is not exhaustive; will be provided in the final report
Related Reports
Community-Acquired Bacterial Pneumonia (CABP) Market Insight, Epidemiology and Market Forecast -2030
DelveInsight’s “Community-Acquired Bacterial Pneumonia (CABP) Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Community-Acquired Bacterial Pneumonia (CABP), historical and forecasted epidemiology as well as the Community-Acquired Bacterial Pneumonia (CABP) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Community-Acquired Bacterial Pneumonia (CABP) Pipeline Insights, 2020
Community-Acquired Bacterial Pneumonia (CABP) Pipeline Insight, 2020 report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Community-Acquired Bacterial Pneumonia (CABP) market.
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.
Contact us
Shruti Thakur
[email protected]
+91-9650213330
https://www.delveinsight.com/
LinkedIn | Facebook | Twitter
Community-Acquired Bacterial Pneumonia (CABP) Epidemiology Report:
https://www.delveinsight.com/sample-request/community-acquired-bacterial-pneumonia-cabp-epidemiology-forecast